Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 8/20 | 0.45 |
| ▸ | QPCTL | Q9NXS2 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397418 | 0.80 | QPCTL (0.57) | QPCTQPCTLROCK1 | |
| SCHEMBL2396266 | 0.79 | QPCTL (0.46) | QPCTQPCTLSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2396653 | 0.73 | QPCTL (0.58) | QPCTQPCTLROCK1 | |
| SCHEMBL2096521 | 0.72 | MMP12 (0.55) | QPCTQPCTLALDH1A1MMP12LMNA | |
| SCHEMBL2398225 | 0.72 | QPCT (0.46) | QPCTQPCTL | |
| SCHEMBL2397076 | 0.71 | QPCTL (0.46) | QPCTQPCTLSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2396832 | 0.70 | QPCTL (0.50) | QPCTQPCTLSMN1; SMN2ALDH1A1TAAR1 | |
| SCHEMBL2397375 | 0.69 | QPCTL (0.85) | QPCTQPCTL | |
| SCHEMBL2397110 | 0.69 | QPCTL (0.85) | QPCTQPCTLROCK2CDC7 | |
| SCHEMBL14669369 | 0.68 | MMP12 (0.52) | QPCTQPCTLSMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542549-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-05-11 | — | — | EP | claimed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | claimed |
| EP-2542549-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-05-11 | — | — | EP | disclosed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20110224259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224259-A1 | NOVEL INHIBITORS | QPCT, GLUL, GLS | QPCT 1/4885QPCTL 5/4885SMN1; SMN2 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.